Address
Division of Oncology Research
Department of Oncology
1321C Guggenheim Building
Mayo Clinic & Foundation
Rochester, Minnesota 55905
Telephone: (507) 284 2424, FAX: (507) 284-3906,
e-mail: ames.matthew@mayo.edu

Date and Place of Birth
December 17, 1947; Richland, Washington

Citizenship
United States

Marital Status
Married

Education
1975-1977 - Staff Research Associate: Pharmacology Research Associate Training Program (PRAT) Fellowship, Section on Biochemical Pharmacology, Hypertension Endocrine Branch, NHLBI, NIH, Bethesda, Maryland; Dr. Walter Lovenberg, Preceptor.

1971-1975 Ph.D., Pharmaceutical Chemistry, University of California, San Francisco, Research Advisor: Neal Castagnoli, Jr., Ph.D.

1966-1970 B.A., Chemistry, Whitman College, Walla Walla, Washington

1961-1966 Mead High School, Spokane, Washington (Class Salutatorian)

Positions and Honors

Professional Experience
2007-present Sandra J. Schulze Endowed Professor
2003-Present Associate Medical Director of Development-Cancer, Mayo Foundation.
2003-Present Chair, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Medical School and Mayo Graduate School.
1993-1999 Director for Research, Mayo Foundation, Rochester.
1989-Present Professor of Pharmacology, Mayo Medical School and Mayo Graduate School.
1987-2003 Chair, Division of Developmental Oncology Research, Department of Oncology, Mayo Foundation.
1981-1989 Associate Professor of Pharmacology, Mayo Medical School and Mayo Graduate School.
1980-Present Consultant, Division of Developmental Oncology Research, Department of Oncology, Mayo Clinic and Foundation .
1978-1980 Associate Consultant, Division of Developmental Oncology Research, Department of Oncology, Mayo Clinic and Foundation; Assistant Professor of Pharmacology, Mayo Medical School and Mayo Graduate School.
1977-1978 Senior Research Associate, Division of Developmental Oncology Research, Department of Oncology, Mayo Foundation; Instructor of Pharmacology, Mayo Medical School and Mayo Graduate School.
1973-1975 Research Assistant in Mass Spectrometry Laboratory, Department of Pharmaceutical Chemistry, University of California, San Francisco, California.
1970-1971 Staff Research Assistant, Chemistry Department, Pomona College, Claremont, California; Drs. R. Nelson Smith and Corwin Hansch.

Memberships in Scientific Societies
American Association for the Advancement of Science
American Society for Pharmacology and Experimental Therapeutics
American Association of Cancer Research
American Society for Pharmacology and Therapeutics

Institutional Activities
Mayo Rochester Research
Research Committee, 1987-1999
Fiscal Subcommittee, 1989-1992
Chair, Fiscal Subcommittee, 1991-1992
Chair, Research Committee, 1993-1999
Director for Research, 1993-1999


Mayo Rochester Board of Governors
Chair, Distinguished Investigator Selection Committee, 1993-1999
Personnel Committee, 1993-2000
Diversity Committee, 1993-1996
Finance Committee, 1995-1999
Annual Planning and Strategic Work Group, 1995-1999
Mayo Regional Healthcare Network Group, 1996-1998
Administrative Committee, 1997-2000

Mayo Foundation
Continuous Improvement Council, 1993-1995
Strategic Alliances Committee, 1993-2000
Diversity Committee, 1993-1996
Research Liaison Committee, 1993-1997
Development Policy Committee, 1994-2000
Medical Industry Relations Committee, 1999-present
Medical Industry Relations Committee, Executive Subcommittee, 2001-present
Embryonic Stem Cell Policy Task Force, 2001
Director for Research Nominating Task Force, 2004
Mayo Comprehensive Cancer Center Director Search Committee, 2005
Named Professorship Committee, 2007-present
Chair, Stem Cell Research Task Force, 2007

Department of Oncology
Staff member, 1977-present
Oncology Research Committee, 1987-1993
Oncology Education Committee, 1987-1992
Executive Committee, 1987-2003

Department of Molecular Pharmacology and Experimental Therapeutics
Faculty Member, 1977-present
Graduate Program Director, 1999-2003
Chair, 2003-present

Mayo NCI Cancer Center
Member, 1976-present
Advisory Committee, 1987-present
Developmental Therapeutics Program, 1977-present
Leader, Developmental Therapeutics Program, 1987-present
Executive Committee, 1995-present

Mayo Graduate School

Course Director, Readings in Pharmacology Graduate Course (Phar 8800), 1986-1993, 2000-2003

Lecturer, Drug Metabolism, Carcinogenesis and Pharmacogenomics (Phar 8805), 1978-present

Lecturer, Tumor Biology (TB 8000), 1983-2003

Lecturer, Toxicology Graduate Course (Phar 8810), 1988-1992

Lecturer, Cellular Pharmacology Course (Phar 8811), 1996-2003

Faculty Member, Neuroscience Program, 1999-present

Member, Graduate School Education Committee, 1999-2003

1. Ames MM Castagnoli N Jr. The synthesis of 13C enriched alpha-methyldopa. J Labeled Compds 1974; 10:195 205.
2. Smith RN, Hansch C, Ames MM. Selection of a reference partitioning system for drug design work. J Pharm Sci 1975 Apr; 64(6):599 606.
3. Ames MM, Nelson SD, Lovenberg W, Sasame HA. Metabolic activation of para chloroamphetamine to a chemically reactive metabolite. Comm Psychopharmacol 1977; 1:455 460.
4. Ames MM, Melmon KL Castagnoli N Jr. Stereochemical course in vivo of alpha methyldopa decarboxylation in rat brains. Biochem Pharmacol 1977; 26(9):1757 1762.
5. Gal J, Ames MM. Gas chromatographic resolution of the enantiomers of 3 (3,4 dihydroxyphenyl)alanine and its a methyl analog. Anal Biochem 1977; 83:266 273.
6. Lerner P, Ames MM, Lovenberg W. The effect of ethylene glycol bis(ß aminoethyl ether) N,N' tetraacetic acid and calcium on tyrosine hydroxylase activity. Mol Pharmacol 1977; 13:44 49.
7. Lerner P, Hartman P, Ames MM, Lovenberg W. The role of reductants in the tyrosine hydroxylase reaction. Arch Biochem Biophys 1977; 182:164 170.
8. Sasame HA, Ames MM, Nelson SD. Cytochrome P 450 and NADPH cytochrome c reductase in rat brain: formation of catechols and reactive catechol metabolites. Biochem. Biophys. Res. Commun 1977, 78(3):919 926.
9. Ames MM, Lerner P, Lovenberg W. Tyrosine hydroxy¬lase: activation by protein phosphorylation and end product inhibition. J Biol Chem 1978; 253:27 31.
10. Lerner P, Nose P, Ames MM, Lovenberg W. Modification of the tyrosine hydroxylase assay: increased enzyme activity in the presence of ascorbic acid. Neurochem Res 1978; 3:641 651.
11. Flora KP, Cradock JC, Ames MM. A simple method for the estimation of amygdalin in urine. Res Comm Chem Pathol Pharmacol 1978; 20:367 378.
12. Ames MM, Kovach JS, Flora KP. Initial pharmacologic studies of amygdalin (laetrile) in man. Res Comm Chem Pathol Pharmacol 1978; 22(1):175 185.
13. Ames MM, Powis G. Determination of indicine N oxide and indicine in plasma and urine by electron capture gas-liquid chromatography. J Chromatogr 1978; 166:519 526.
14. Kovach JS, Ames MM, Sternad ML, O'Connell MJ. Phase I trial and assay of rubidazone (NSC 164011) in patients with advanced solid tumors. Cancer Res 1979; 39:823 828.
15. Ames MM, Powis G, Kuehn PW. Determination of pyrazoloimidazole in plasma and urine by gas liquid chromatography using nitrogen phosphorus detection. J Chromatogr 1979; 169:412 415.
16. Powis G, Ames MM. Determination of L alanosine in plasma and urine by reversed phase high performance liquid chromatography of the Dns derivative. J Chromatogr 1979; 170:195 201.
17. Ames MM, Powis G. Determination of pentamethylmelamine and hexamethylmelamine in plasma and urine by nitrogen phosphorus gas liquid chromatography. J Chromatogr 1979; 174:245 249.
18. Powis G, Ames MM, Kovach JS. Relationship of the reductive metabolism of indicine N oxide to its antitumor activity. Res Comm Chem Pathol Pharmacol 1979; 24(3):559 569.
19. Powis G, Ames MM, Kovach JS. Metabolic conversion of indicine N oxide to indicine in rabbits and humans. Cancer Res 1979; 39:3564 3570.
20. Kovach JS, Ames MM, Powis G, Moertel CG, Hahn RG, Creagan ET. Toxicity and pharmacokinetics of a pyrrolizidine alkaloid, indicine N oxide, in humans. Cancer Res 1979; 39:4540 4544.
21. Ames MM, Powis G, Kovach JS, Eagan RT. Disposition and metabolism of pentamethylmelamine and hexamethylmelamine in rabbits and humans. Cancer Res 1979; 39:5016 5021.
22. Powis G, Ames MM. Determination of 6 diazo 5 oxo L¬ norleucine in plasma and urine by reversed phase high performance liquid chromatography of the dansyl derivative. J Chromatogr 1980; 181:95 99.
23. Lieber MM, Ames MM, Powis G, Kovach JS. Anticancer drug testing in vitro: use of an activating system with the human tumor stem cell assay. Life Sci 1981; 28:287 293.
24. Letendre L, Smithson WA, Gilchrist GS, Burgert EO Jr, Hoagland CH, Ames MM, Powis G, Kovach JS. Activity of indicine N oxide in refractory acute leukemia. Cancer 1981; 47(3):437 441.
25. Moertel CG, Ames MM., Kovach JS, Moyer TP, Rubin JR, Tinker, JH. A pharmacologic and toxicological study of amygdalin. J Am Med Assoc. 1981; 245(6):591 594.
26. Ames MM, Moyer TP, Kovach JS, Moertel CG, Rubin J. Pharmacology of amygdalin (laetrile) in cancer patients. Cancer Chemother Pharmacol 1981; 6:51-57.
27. Powis G, Ames MM, Kovach JS. Dose dependent pharmacokinetics and cancer chemotherapy. A review. Cancer Chemother Pharmacol 1981; 6:1 9.
28. Ames MM, Sanders ME, Tiede WS. Metabolic activation of hexamethylmelamine and pentamethylmelamine by liver microsomal preparations. Life Sci 1981; 29:1591 1598.
29. Eagan RT, Ames MM, Powis G, Kovach JS. Clinical and pharmacologic evaluation of split dose intermittent therapy with dianhydrogalactitol (NSC 132313). Cancer Treat Rep 1982; 66:283 287.
30. Ames MM, Frank SK. Stereochemical aspects of para chloro¬amphetamine metabolism. Rabbit liver microsomal metabolism of RS, R( ), and S(+) para chloroamphetamine. Biochem Pharmacol 1982; 31(1):5 9.
31. Ames MM, Kovach JS. Parenteral formulation of hexamethylmelamine potentially suitable for use in man. Cancer Treat Rep 1982; 66(7):1579 1581.
32. Ames, MM., Miser JS, Smithson WA, Coccia PF, Hughes CS, Davis DM. Pharmacokinetic study of indicine N oxide in pediatric cancer patients. Cancer Chemother Pharmacol 1982; 10(1):43 46.
33. Ames MM, Sanders ME, Tiede WS. Role of N methylol-pentamethylmelamine in the metabolic activation of hexamethylmelamine. Cancer Res 1983; 43:500 504.
34. Agrez MV, Ames MM, Lieber MM. In vitro chemotherapy sensitivity patterns of human colon carcinoma continuous cell lines. J Surg Oncol 1983; 24:79 82.
35. Woodson LC, Ames MM, Selassie CD, Hansch C, Weinshilboum RM. Thiopurine methyltransferase: aromatic thiol substrates and inhibition by benzoic acid derivatives. Mol Pharm 1983; 24:471 478.
36. Miller KJ, Gal J, Ames MM. High performance liquid chromatographic resolution of enantiomers of l phenyl 2 aminopropanes (amphetamines) with four chiral reagents. J Chromatogr 1984; 307:335 342.
37. Sanders ME, Ames MM. Synthesis of N methylolpentamethyl-melamine (ring 14C), a cytotoxic-alkylating metabolite of hexamethyl¬melamine. J Lab Comp Radiopharmaceut 1984; 21(10):893 898.
38. Frytak S, Eagan RT, Ames MM, Creagan ET, Nichols WC. Phase I study of diaziquone. Cancer Treat Rep 1984; 68:975 978.
39. Ames MM, Kovach JS Rubin J. Pharmacologic characterization of teroxirone, a triepoxide antitumor agent, in rats, rabbits, and humans. Cancer Res 1984; 44:4151 4156.
40. Agrez MV, Ames MM, Lieber MM, Tyce GM. The Presence of serotonin in animal sera used in cell culture. Biogenic Amines 1984;1:223 228.
41. Moertel CG, Fleming TR, Creagan ET, Rubin J, O'Connell MJ, Ames MM. High-dose vitamin c versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy: a randomized double-blind comparison. N Eng J Med 1985; 312:137 141.
42. Miller KJ, McGovern R, Ames MM. Effect of hepatic activation system on the antiproliferative activity of hexamethylmelamine against human tumor cell lines. Cancer Chemother Pharmacol 1985; 15:49 53.
43. Ames MM, Miller KJ, Moertel DM. High performance liquid chromatographic assay and preclinical pharmacological studies of pibenzimol (bisbenzimidazole). J Chromatogr, Biomed Appl 1985; 341:89 96.
44. Sanders ME, Ames MM. Acylhydroperoxide oxidations of the anticancer agent hexamethylmelamine. Tetrahedron Lett 1985; 26:5247.
45. Ames MM, Selassie CD, Woodson LC, Van Loon JA, Hansch C, Weinshilboum RM. Thiopurine methyltransferase: structure activity relationships for benzoic acid inhibitors and thiophenol substrates. J Med Chem 1986; 29(3):354 358.
46. Miller KJ, Anderholm DC, Ames MM. Metabolic activation of the serotonergic neurotoxin para chloroamphetamine to chemically reactive intermediates by hepatic and brain microsomal preparations. Biochem Pharmacol 1986; 35(10):1737-1742.
47. Frank SK, Mathiesen DA, Whitfield LR, Ames MM. High performance liquid chromatographic assay for the experimental anticancer agent oxantrazole. J Chromatogr, Biomed Appl 1987; 419:225 232.
48. Rubin J, Kovach JS, Ames MM, Moertel CG, Creagan, ET, O'Connell, MJ. Phase I study of two schedules of teroxirone. Cancer Treat Rep 1987; 71(5):489 492 .
49. Campbell NRC, Van Loon JA, Sundaram RS, Ames MM, Hansch C, Weinshilboum R. Human and rat liver phenol sulfotransferase: structure activity relationships for phenolic substrates. Mol Pharm 1987; 32:813 819.
50. Kinder DH, Ames MM. Synthesis of 2 amino 3 boronopropionic acid: a boron containing analog of aspartic acid. J Org Chem 1987; 52(12):2452 2454.
51. Kovach JS, Richardson RL. and Ames MM. Cisplatinum: New clinical applications. Excerpta Medica, Ltd 1987; 2:298 307.
52. Rubin J, Ames MM, Schutt AJ, Fitch TR, Cole TL, Bowie EJW, Kovach JS. Flavone 8 acetic acid, an anticancer drug, inhibits von willebrand factor mediated platelet function. Lancet 1988; 2:1081 1082.
53. Frank SK, Mathiesen DA, Szurszewski M, Kuffel MJ, Ames MM. Preclinical pharmacology of the anthrapyrazole analog oxantrazole (NSC 349174). Cancer Chemother Pharmacol 1989; 23(4):213-218.
54. Ames MM, Mathiesen DA. High performance liquid chromatographic assay and preclinical pharmacologic studies with the experimental antitumor agent batracylin. J Chromatogr, Biomed.Appl 1989; 491(2):488-494.
55. Ames MM, Richardson RL, Kovach JS, Moertel CG, O'Connell MJ. Phase I and clinical pharmacologic evaluation of a parenteral hexamethylmelamine formulation. Cancer Res 1990; 50:206-210 (1990).
56. Kinder DH, Frank SK, Ames MM. Analogues of carbamyl aspartate as inhibitors of dihydroorotase: preparation of boronic acid transition-state analogues and a zinc chelator carbamylhomocysteine. J Med Chem 1990; 33(2):819-823.
57. Ames MM, Loprinzi CL, Collins JM., van Haelst-Pisani CM, Richardson RL, Rubin J, Moertel CG. Phase I and clinical pharmacologic evaluation of pirozantrone hydrochloride (oxantrazole). Cancer Res 1990; 50:3905-3909.
58. Loprinzi CL, Love RR, Garrity JA, Ames MM. Cyclophosphamide, methotrexate and 5-fluorouracil (CMS)-induced ocular toxicity. Cancer Invest 1990; 8:459-465.
59. Reid JM, Pendergrass TW, Krailo MD, Hammond GD, Ames MM. Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients. A Childrens Cancer Study Group Report. Cancer Res 1990; 50:6525-6528.
60. Mayeno AN, Lin F, Foote CS, Loegering DA, Ames MM, Hedberg CW, Gleich GJ. Characterization of "Peak E", a novel amino acid associated with Eosinophilia-Myalgia syndrome. Science 1990; 250:1707-1708.
61. Patel SR, Kvols LK, Rubin J, O'Connell MJ, Edmonson JH, Ames MM, Kovach JS. Phase I-II study of pibenzimol hydrochloride (NSC 322921) in advanced pancreatic carcinoma. Invest. New Drugs 1991; 9:53-57.
62. Ames MM. Hexamethylmelamine: Pharmacology and mechanism of action. Cancer Treat Re 1991; 18 (Supplement A):3-14.
63. Ames MM, Mathiesen DA, Reid JM. Differences in N-acetylation of the experimental antitumor agent batracylin in the mouse and the rat. Invest New Drugs 1991; 9:219-225.
64. Ames MM, Spreafico F. Selected pharmacologic characteristics of idarubicin and idarubicinol. Leukemia 1992; 6(Suppl 1):70-75.
65. Kuffel MJ, Reid JM, Ames MM. Anthracyclines and their c-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture. Cancer Chemother Pharmacol 1992; 30:51-57.
66. Reid JM, Mathiesen DA, Benson LM, Kuffel MJ, Ames MM. Murine pharmacokinetics and metabolism of penclomedine [3,5-dichloro-2,4-dimethoxy-6-(trichloromethyl)-pyridine, NSC 338720]. Cancer Res 1992; 52:2830-2834.
67. Kinder DH, Elstad CA, Meadows GG, Ames MM. Antimetastatic activity of boro-amino acid analog protease inhibitors against B15Bl6 melanoma in vivo. Invasion and Metastasis 1992; 12:309-319.
68. Davis T, Miser AW, Loprinzi CL, Kaur JS, Burnham NL, Dose AM, Ames MM. Comparative morphine pharmacokinetics following sublingual, intramuscular and oral administration in patients with cancer. The Hospice J 1993; 9(1):85-90.
69. Zembower DE, Gilbert JA, Ames MM. Enantiospecific syntheses of ?-fluoromethyltryptophan analogues: interactions with tryptophan hydroxylase and aromatic-l-amino acid decarboxylase. J Med Chem 1993; 36:305-313.
70. Blaney SM, Balis FM, Cole DE, Craig C, Reid JM, Ames MM, Krailo M, Reaman G, Hammond D, Poplack DG. Pediatric Phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion. Cancer Res 1993; 53:1032-1036.
71. Benson LM, Tomlinson AJ, Reid JM, Walker DL, Ames MM, Naylor S. Study of in vivo pyrazoloacridine metabolism by capillary electrophoresis using isotachophoresis preconcentration in non-aqueous separation buffer. J High Resolution Chromatogr 1993; 16:324-326.
72. Tefferi A, Silverstein MN, Plumhoff EA, Reid JM, Ames MM. Suramin toxicity and efficacy in agnogenic myeloid metaplasia. J Natl Cancer Inst 1993; 85(18):1520-1522.
73. Tefferi A, Witzig TE, Reid JM, Li C-Y, Ames MM. Phase I study of combined 2-chlorodeoxyadenosine and chlorambucil in chronic lymphoid leukemia and low- grade lymphoma. J Clin Oncol 1994; 12(3):569-574.
74. Walker DL, Reid JM, Ames MM. Preclinical pharmacology of Bizelesin, a potent bifunctional analog of the DNA-binding antibiotic CC-1065. Cancer Chemother Pharmacol 1994; 34(4):317-322.
75. Zembower DE, Ames MM. Synthesis of 5-alkyl- and 5-aryl-L-tryptophan analogues via palladium-catalyzed cross-coupling of an iodinated cyclic tryptophan tautomer. Synthesis 1994; 12:1433-1436.
76. Dhodapkar MV, Richardson RL, Reid JM, Ames MM. Pyrazine diazohydroxide (NSC-361456): Phase I clinical and pharmacokinetic studies. Invest New Drugs 1994; 12:207-216.
77. Reid JM, Benson JW, Viallet J, Ames, MM. Preclinical pharmacology of cholera toxin (NSC 629801). Cancer Chemother Pharmacol 1995; 36(2):115-120.
78. Kuffel MJ, Ames MM. Comparative resistance of idarubicin, doxorubicin and their C-13 alcohol metabolites in human MDR1 transfected NIH-3T3 cells. Cancer Chemother Pharmacol 1995; 36(3):223-226.
79. Gilbert JA, Bates LA, Ames MM. Elevated aromatic-L-amino acid decarboxylase in human carcinoid tumors. Biochem Pharmacol 1995; 50(6):845-850.
80. Haddock MG, Ames MM, Bonner JA. Assessing the interaction of radiation with etoposide or idarubicin. Mayo Clin Proc 1995; 70:1-8.
81. Hartmann LC, Ames MM, Reid JM, Richardson RL. Phase I trial of diaziquone (AZQ) plus GM-CSF. Invest New Drugs 1995; 13:175-176.
82. Reid JM, Walker DL, Ames MM. Preclinical pharmacology of ecteinascidin 729, a marine natural product with potent antitumor activity. Cancer Chemother Pharmacol 1996; 38:329-334.
83. Feig SA, Ames MM, Sather HN, Steinherz L, Reid JM, Trigg M, Pendergrass TW, Warkentin P, Gerber, M, Leonard M, Bleyer WA, Harris RE. Comparison of idarubicin to daunomycin in a randomized multidrug treatment of childhood acute lymphoblastic leukemia at first bone marrow relapse: A report from the Childrens Cancer Group. Med Ped Oncol 1996; 27:505-514.
84. Zembower DE, Neudauer CL, Wick MJ, Ames MM. Peptide Boronic Acids: Versatile synthetic ligands for affinity chromatography of serine proteinases. Inter J Peptide Protein Res 1996; 47(5):405-413.
85. Dhodapkar M, Rubin J, Reid JM, Burch PA, Pitot HC, Buckner JC, Ames MM, Suman VJ. Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer. Clin Cancer Res 1997; 3(7):1093-1100.
86. Lawrence JB, Conover CA, Haddad TC, Ingle JN, Reid JM, Ames MM, Suman VJ, Marks RS, Erlichman C, Hartmann LC. Evaluation of continuous infusion suramin in metastatic breast cancer: Impact on plasma levels of insulin-like growth factors (IGFs) and IGF-binding factor proteins. Clin Cancer Res 1997; 3:1713-1720.
87. Goldberg RM, Reid JM, Ames MM, Sloan JA, Rubin J, Erlichman C, Kuffel MJ, Fitch TR. Phase I and pharmacologic trial of fazarabine (Ara-AC) with granulocyte colony-stimulating factor. Clin Cancer Res 1997; 3:2363-2370.
88. Reid JM, Stevens DC, Rubin J, Ames MM. Pharmacokinetics of 3-methyl-(triazen-1-yl)imidazole-4-carboximide following administration of temozolomide to patients with advanced cancer. Clin Cancer Res 1997; 3:2393-2398.
89. Budihardjo II, Walker DL, Svingen PA, Buckwalter CA, Desnoyers S, Eckdahl S, Shah GM, Poirier GG, Reid JM, Ames MM, Kaufmann SH. 6-Aminonicotinamide sensitizes human tumor cell lines to cisplatin. Clin Cancer Res 1998; 4:117-130.
90. Adjei AA, Charron M, Rowinsky EK, Svingen PA, Miller J, Reid JM, Sebolt-Leopold J, Ames MM, Kaufmann SH. Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II. Clin Cancer Res 1998; 4:683-691.
91. Alberts SR, Erlichman C, Reid JM, Sloan JA, Ames MM, Richardson RL, Goldberg RM. Phase I study of the duocarmycin semisynthetic derivative KW-2189 given daily for five days every six weeks. Clin Cancer Res 1998; 4:2111-2117.
92. Rajkumar SV, Buckner JC, Schomberg PJ, Reid JM, Bagniewski PJ, Ames MM, Cascino TL, Marks RS. Phase I and pharmacokinetic study of preirradiation chemotherapy with BCNU, cisplatin, etoposide and accelerated radiation therapy in patients with high-grade glioma. Int J Rad Oncol Biol Phys 1998; 42:969-975.
93. Nicholson HS, Krailo M, Ames MM, Seibel NL, Reid JM, Liu-Mares W, Vezina LG, Ettinger, AG. Reaman GH. Phase I study of temozolomide in children and adolescents with recurrent solid tumors: A report from the Children’s Cancer Group. J Clin Oncol 1998; 16(9):3037-3043.
94. Balis FM, Holcenberg JS, Poplack DG, Ge J, Sather HN, Murphy RF, Ames MM, Waskerwitz MJ, Tubergen DG, Zimm S, Gilchrist GS, Bleyer WA. Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: A joint Children’s Cancer Group and Pediatric Oncology Branch Study. Blood 1998; 92(10):3569-3577.
95. Zembower DE, Zhang H, Lineswala JP, Kuffel MJ, Aytes SA, Ames MM. Indolocarbazole poisons of human topoisomerase I: regioisomeric analogues of ED-110. Bioorg Med Chem Lett 1999; 9:145-150.
96. Berg SL, Reid JM, Godwin K, Murry DJ, Poplack DG, Balis FM, Ames MM. Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model. J Ped Hematol Oncol 1999; 21(1):26-30.
97. Buckner JC, Malkin MG, Reed E, Cascino TL, Reid JM, Ames MM, Tong WPY, Lim S, Figg WD. Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 6209261) in patients with recurrent glioma. Mayo Clinic Proc 1999; 74:137-145.
98. Pitot HC, McElroy EA Jr, Reid JM, Windebank AJ, Sloan JA, Erlichman C, Bagniewski PG, Walker DL., Rubin J, Goldberg RM, Adjei AA, Ames MM. Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors. Clin Cancer Res 1999; 5:525-531.
99. Reid JM, Kuffel MJ, Miller JK, Rios R, Ames MM: Metabolic activation of dacarbazine by human cytochromes P450: The role of the CYP1A1, CYP1A2 and CYP2E1. Clin Cancer Res 1999; 5:2192-2197.
100. Walker DL, Reid JM, Svingen PA, Rios R, Covey JM, Alley MC, Hollingshead MG, Budihardjo II, Eckdahl S, Boerner SA, Kaufmann SH, Ames MM. Murine pharmacokinetics of 6-aminonicotinamide (NSC 21206), a novel biochemical modulating agent. Biochem Pharmacol 1999; 58:1057-1066.
101. Frangoul H, Ames MM, Mosher RB, Reid JM, Krailo MD, Seibel NL, Shaw DWW, Steinherz PG, Whitlock JA, Holcenberg JS. Phase I study of topotecan administered as a 21-day continuous infusion in children with recurrent solid tumors. A report from the Children’s Cancer Group. Clin Cancer Res 1999; 5:3956-3962.
102. Budihardjo II, Boerner SA, Eckdahl S, Svingen PA, Rios R, Ames MM, Kaufmann SH. Effect of 6-Aminonicotinamide and other protein synthesis inhibitors on formation of platinum-DNA adducts and cisplatin sensitivity. Mol Pharmacol 2000; 57:529-538.
103. Gilbert JA, Frederick LM, Ames MM. The Aromatic-L-Amino acid decarboxylase inhibitor carbidopa is selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells. Clin Cancer Res 2000; 6:4365-4372.
104. Rajkumar SV, Reid JM, Novotny PJ. Safgren SL, Scheithauer BW, Johnson PS, Nair S, Morton RF, Hatfield AK, Krook JE, Ames MM, Buckner JC. A randomized Phase II and pharmacokinetic study of dacarbazine in patients with recurrent glioma. J Neuro-Oncol 2000; 49:255-261.
105. Bracho F, Krailo MD, Shen V, Bergeron S, Davenport V, Liu-Mares W, Blazar BR, Panoskaltsis-Mortari A, van de Ven C, Secola R, Ames MM, Reid JM, Reaman GH, Cairo MS. A Phase I clinical, pharmacologic and biological trial of interleukin-6 plus granulocyte-colony stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent/refractory solid tumors: Enhanced hematological responses but a high incidence of grade III/IV constitutional toxicities. Clin Cancer Res 2001; 7:58-67.
106. Galanis E, Goldberg R, Reid J, Atherton P, Sloan J, Pitot H, Rubin J, Adjei AA, Burch P, Safgren SL, Witzig TE, Ames MM, Erlichman C. Phase I trial of sequential administration of raltitrexed (Tomudex) and 5-iodo-2'-deoxyuridine (IdUrd). Ann Oncol 2001; 12:701-707.
107. Safgren SL, Reid JM, Rios R, Ames MM. Validated high-performance liquid chromatographic assay for simultaneous determination of dacarbazine and the plasma metabolites 5-(3-hydrxoymethyl-3-methyl-1-triazeno)imidazole-4-carboxamide and 5-(3-methyl-1-triazeno)imidazole-4-carboxamide. J Chromatogr 2001; 754:91-96.
108. Wells RJ, Reid JM, Ames MM, Mares WL, Krailo MD, Seibel NL, Mosher R, Reaman GH, Wiersma SR. Phase I trial of cisplatin and topotecan in children with recurrent solid tumors: Children's Cancer Group Study 0942. J Pediatric Hematol Oncol 2002; 24(2):89-93.
109. Pitot HC, Reid JM, Sloan JA, Ames MM, Adjei AA, Rubin J, Bagniewski PG, Atherton P, Rayson D, Goldberg RM, Erlichman C. A Phase I study of bizelesin (NSC 615291) in patients with advanced solid tumors. Clin Cancer Res 2002; 8(3):712-717.
110. Adjei AA, Reid JM, Diasio RB, Sloan JA, Smith DA, Rubin J, Pitot HC, Alberts SR, Goldberg RM, Hanson LJ, Atherton P, Ames MM, Erlichman C. Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors. J Clin Oncol 2002; 20(6):1683-1691.
111. Kuffel MJ, Schroeder JC, Pobst LJ, Naylor S, Reid JM, Kaufmann SH, Ames MM. Activation of the antitumor agent aminoflavone (NSC 686288) is mediated by induction of tumor cell cytochrome P450 1A1/1A2. Mol Pharm 2002; 62:143-153.
112. Reid JM, Kuffel MJ, Ruben SL, Morales JJ, Rinehart KL, Squillace DP, Ames MM. Rat and human liver cytochrome P-450 isoform metabolism of ecteinascidin 743 does not predict gender-dependent toxicity in humans. Clin Cancer Res 2002; 8:2952-2962.
113. Adjei AA, Reid JM, Erlichman C, Sloan JA, Pitot HC, Alberts SR, Goldberg RM, Hanson LJ, Ruben S, Boerner SA, Atherton P, Ames MM, Kaufmann SH. A Phase I and pharmacologic study of pyrazoloacridine (NSC 366140) and carboplatin in patients with advanced cancer. Invest New Drugs 2002; 20:297-304.
114. Steinherz PG, Siebel NL, Ames MM, Avramis VI, Krailo MD, Liu-Mares W, Reid JM, Safgren SL, Reaman GH. Phase I study of gemcitabine (difluorodeoxycytidine) in children with relapsed or refractory leukemia (CCG-0955): A report from the Children's Cancer Group. Leuk Lymphoma 2002; 43(10):1945-1950.
115. Reid JM, Squillace DP, Ames MM. Single-dose pharmacokinetics of the DNA-binding bioreductive agent NLCQ-1 (NSC 709257) in CD2F1 mice. Cancer Chemother Pharmacol 2003; 51:483-4387.
116. Goetz MP, Toft DO, Ames MM, Erlichman C. The Hsp90 chaperone complex as a novel target for cancer therapy. Ann Oncol 2003; 14:1169-1176.
117. Goetz MP, Erlichman C, Windebank AJ, Reid JM, Sloan JA, Atherton P, Adjei AA, Rubin J, Pitot H, Galanis E, Ames MM, Goldberg RM. Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, fluorouracil and leucovorin in patients with solid tumors. J Clin Oncol 2003; 21(20):3761-3769.
118. Reid JM, Walker DL, Miller JK, Benson LM, Tomlinson AJ, Naylor S, Blajeski AL, LoRusso PM, Ames MM. The metabolism of pyrazoloacridine (NSC 366140) by cytochromes P450 and flavin monooxygenase in human liver microsomes. Clin Cancer Res 2004; 10:1471-1480.
119. Goetz MP, Ames MM, Weinshilboum RM. Primer on medical genomics Part XII: Pharmacogenomics--general principles with cancer as a model. Mayo Clinic Proc 2004; 79:376-384.
120. Reid JM, Qu W, Safgren SL, Ames MM, Krailo MD, Seibel NL, Kuttesch J, Holcenberg J. Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors. J Clin Oncol 2004; 22(12):2445-2451 (2004).
121. Goetz MP, Toft D, Reid J, Ames M, Stensgard B, Safgren S, Adjei AA, Sloan J, Atherton P, Vasile V, Salazaar S, Adjei, A, Croghan G, Erlichman C. Phase I trial of 17-allylamino-geldanamycin in patients with advanced cancer. J Clin Oncol 2005; 23(6):1078-1087.
122. Gilbert JA, Frederick LM, Pobst LJ, Ames MM. Hydrogen peroxide degradation and selective carbidopa-induced cytotoxicity against human tumor cell lines. Biochem Pharmacol 2005; 69:1159-1166.
123. Gilbert JA, Lloyd RV, Ames MM. Lack of Mutations in EGFR in Gastroenteropancreatic Neuroendocrine Tumors. (letter). N Engl J Med 2005; 353:209-210.
124. Bible KC, Lensing J.L, Nelson SA, Lee YK, Reid JM, Ames MM, Isham CR, Piens J, Rubin SL, Rubin J, Kaufmann SH, Atherton PJ, Sloan JA, Daiss MK; Adjei AA, Erlichman C. Phase 1 trial of flavopiridol combined with cisplastin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points. Clin Cancer Res 2005; 11(16):5935-5941.
125. Kaufmann SK, Karp JE, Letendre L, Kottke TJ, Safgren S, Greeer J, Gojo I, Atherton P, Svingen PA, Loegering DA, Litzow MR, Sloan JA, Reid JM, Ames MM, Adjei AA, Erlichman C. Phase I and Pharmacologic study of infusional tropotecan and carboplatin in relapsed and refractory acute leukemia. Clin Cancer Res 2005; 11(18):6641-6649.
126. Papouchado B, Erickson LA, Rohlinger AL, Hobday TJ, Erlichman C, Ames MM, Lloyd RV. Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas. Mod Pathol 2005; 18(10):1329-1335.
127. Galanis E, Buckner JC, Maurer MJ, Reid JM, Kuffel MJ, Ames MM, Scheithauer BW, Hammack JE, Pipoly G, Kuross SA. Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: A North Central Cancer Treatment Group Trial. Invest New Drugs 2005; 23(5):495-503.
128. Whitlock JA, Krailo M, Reid JM, Ruben SL, Ames MM, Owen W, Reaman G. Phase I clinical and pharmacokinetic study of flavopiridol in children with refractory solid tumors: A children’s oncology group study. J Clin Oncol 2005; 23(36):9179-9186.
129. Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Flockhart DA, Desta Z, Perez EA, Ingle JN. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005; 23(36):9312-9318.
130. Johansen M, Kuttesch J, Bleyer WA, Krailo M, Ames M, Madden T. Phase I evaluation of oral and intravenous vinorelbine in pediatric cancer patients: A report from the children’s oncology group. Clin Cancer Res 2006; 12(2):516-522.
131. Gilbert JA, Salavaggione OE, Ji Y, Pelleymounter LL, Eckloff BW, Wieben ED, Ames MM, Weinshilboum RM. Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. Clin Cancer Res 2006; 12(6):1794-1803.
132. Pobst LJ, Ames MM. CYP1A1 activation of aminoflavone leads to DNA damage in human tumor cell lines, Cancer Chemother Pharmacol 2006; 57(5)569-576.
133. Villablanca JG, Krailo MD, Ames MM, Reid JM, Reaman GH, Reynolds CP. Phase I trial of oral fenretinide in children with high-risk solid tumors: A report from the Children’s Oncology Group (CCG 09709). J Clin Oncol 2006; 24(1):3423-3430.
134. Buhrow SA, Reid JM, Jia L, McGovern RM, Covey JM, Kobs DJ, Grossi IM, Ames MM. LC-MS/MS assay and dog pharmacokinetics of the dimeric pyrrolobenzodiazepine SJG-136 (NSC 694501). J Chromatogr B: Analyt Technol Biomed Life Sci 2006; 840(1 Special Issue SI):56-62.
135. Goetz MP, Rae JM, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch F, Lingle WL, Flockhart DA, Desta Z, Perez EA, Ingle JN. Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: Data from the Italian tamoxifen trial - Reply. J Clin Oncol 2006; 24(22):3709.
136. Nowakowski GS, McCollum AK, Ames MM, Mandrekar SJ, Reid JM, Adjei AA, Toft DO, Safgren SL, Erlichman C. A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer. Clin Cancer Res 2006; 12(20 Part 1):6087-6093.
137. Goetz MP, Knox SK, Suman VJ, Rae JM, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Weinshilboum RM, Barr Fritcher EG, Nibble AM, Desta Z, Nguyen A, Flockhart DA, Perez EA, Ingle JN. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.. Breast Cancer Res Treat 2007; 101(1):113-121.
138. Weigel BJ, Blaney SM, Reid JM, Safgren, SL, Bagatell R, Kersey J, Neglia JP, Ivy SP, Ingle AM, Whitesell L, Gilbertson RJ, Krailo M, Ames MM, Adamson PC. A Phase I study of 17-allylaminogeldanamycin (17-AAG) in Relapsed/Refractory Pediatric Patients with Solid Tumors: A Children’s Oncology Group Study. Clin Cancer Res 2007; 13(6):1789-93.
139. Le SB, Hailer MK, Buhrow S, Wang Q, Flatten K, Pediaditakis P, Bible KC, Lewis LD, Sausville EA, Pang Y-P, Ames MM, Lemasters JJ, Holmuhanedov EL, Kaufmann SH. Inhibition of mitochondrial respiration as a source of adaphostin-induced reactive oxygen species and cytotoxicity. J Biol Chem 2007; 282(12):8860-8872.
140. Stapleton SL, Reid JM, Thompson PA, Ames MM, McGovern RM, McGuffey L, Nuchtern J, Dauser R, Blaney SM. Plasma and cerebrospinal fluid pharmacokinetics of pemetrexed after intravenous administration in non-human primates. Cancer Chemother Pharmacol 2007; 59(4):461-466.
141. Malempati S, Nicholson HS, Reid JM, Blaney SM, Ingle AM, Krailo M, Stork LC, Melemed AS, McGovern R, Safgren S, Ames MM, Adamson PC. Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Children's Oncology Group. J Clin Oncol 2007; 25(12):1505-1511.
142. McWilliams RR, Goetz MP, Morlan BW, Salim M, Rowland KM, Krook JE, Ames MM, Erlichman C. Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer. Clin Colorectal Cancer 2007; 6(7):516-521.
143. Alberts SR, Kim GP, Mahoney MR, Gornet MK, Rubin J, Ames M, Goetz MP, Weinshilboum RM, Nicol SJ, Goldberg RM. Pemetrexed and oxaliplatin for metastatic colorectal cancer: results of a phase I Mayo Cancer Center Research Consortium trial, MC0248. Clin Colorectal Cancer 2007; 6(8):572-577.
144. Leil TA, Endo C, Adjei AA, Dy GK, Salavaggione OE, Reid JM, Ames MM, Adjei AA. Identification and characterization of genetic variation in the folylpolyglutamate synthase gene. Cancer Res 2007; 67(18):8772-8782.
145. Myers RM, Greiner SM, Harvey ME, Griesmann G, Kuffel MJ, Buhrow SA, Reid JM, Federspiel M, Ames MM, Dingli D, Schweikart K, Welch A, Dispenzieri A, Peng K-W, Russell SJ. Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide. Clin Pharmacol Ther 2007; 82(6):700-710.
146. Furth AF, Mandrekar SJ, Tan AD, Rau A, Felten SJ, Ames MM, Adjei AA, Reid JM, Erlichman C. A limited sample model to predict area under the drug concentration curve for 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite 17-(amino)-17-demethoxygeldanomucin. Cancer Chemother Pharmacol 2008; 61:39-45.
147. Goetz MP, Kamal A, Ames MM. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. Clin Pharmacol Ther 2008; 83(1):160-166.
148. Jia L, Schweikart K, Tomaszewski J, Page JG, Noker PE, Buhrow SA, Reid JM, Ames MM, Munn DH. Toxicology and pharmacokinetics of 1-methyl-D-tryptophan: absence of toxicity due to saturating absorption. Food Chem Toxicol 2008; 46(1):203-211.
149. Patra CR, Bhattacharya R, Wang E, Katarya A, Lau JS, Dutta S, Muders M, Wang S, Buhrow SA, Safgren SL, Yaszemski MJ, Reid JM, Ames MM, Mukherjee P, Mukhopadhyay D. Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent. Cancer Res 2008; 68(6):1970-1978.
150. Reid JM, Mandrekar SJ, Carlson EC, Harmsen WS, Green EM, McGovern RM, Szabo E, Ames MM, Boring D, Limburg PJ. Comparative bioavailability of sulindac in capsule and tablet formulations. Cancer Epidemiol Biomarkers Prev 2008; 17(3):674-679.
151. Horton TM, Ames MM, Reid JM, Krailo MD, Pendergrass T, Mosher R, Reaman GH, Seibel NL. A phase I and pharmacokinetic clinical trial of paclitaxel for the treatment of refractory leukemia in children: a children’s oncology group study. Pediatr Blood Cancer 2008; 50(4):788-792.
152. Reid JM, Mandrekar SJ, Carlson EC, Harmsen WS, Green EM, McGovern RM, Szabo E, Ames MM, Boring D, Limburg PJ. Comparative bioavailability of sulindac in capsule and tablet formulations. Cancer Epidemiol Biomarkers Prev 2008; 17(3):674-679.
153. Gilbert JA, Goetz MP, Reynolds CA, Ingle JN, Giordano KF, Suman VJ, Blair HE, Jenkins RB, Lingle WL, Reinholz MM, Adjei AA, Ames MM. Moleular analysis of metaplastic breast carcinoma: increase EGFR gene copy numbr via aneusomy. Mol Cancer Ther. In Press.
154. Nicholson HS, Reid JM, Blaney SM, Ingle AM, Krailo M, Stork LC, Melemed AS, McGovern RM, Safgren SL, Ames Matthew M.; Adamson, Peter C. Phase I Trial and Pharmacokinetic Study of Pemetrexed in Children with Refractory Solid Tumors: A Report from the Children’s Oncology Group. J. Clin. Oncol., In Press.

Books

1. Ames MM, Powis G, Kovach JS. Pharmacokinetics of anticancer agents in human. Amsterdam: Elsevier; 1983. 479 p.
2. Grochow LB, Ames MM. A Clinician’s Guide to Chemotherapy Pharmacokinetics and Pharmacodynamics. Baltimore: Williams & Wilkins; 1998. 578 p.

Book Chapters

1. Castagnoli N Jr, Melmon KL, Freed CR, Ames MM, Kalir A, Weinkman R. Application of chemical ionisation mass spectrometry and stable isotopes in studies of a methyldopa metabolism. In: Baillie TA, editor. Proceedings of the Symposium on Stable Isotopes: Application in Pharmacology, Toxicology and Clinical Research. Baltimore: University Park Press, 1977, pp. 261-279.
2. Lovenberg W, Ames MM, Lerner P. Regulation of tyrosine hydroxylase activity. In: Costa E, Gessa GL, Editors. Advances in Biochemical Psychopharmacology. New York: Raven Press, 1977, Volume 16, pp. 461-464.
3. Lovenberg W, Ames MM, Lerner P. Mechanism of Short term Regulation in Tyrosine Hydroxylase. In: Lipton MA, DiMascio A, Killam KF, Editors. Psychopharmacology: A Generation of Progress. New York: Raven Press, 1978, pp. 247-259.
4. Lieber MM, Ames MM, Powis G, Kovach JS. Drug sensitivity testing in vitro with a liver microsome "activated" soft agar human stem cell colony assay. In: Fidler IJ, White RJ, Editors. Design of Models for Testing Cancer Therapeutic Agents. New York: Van Nostrand Reinhold Company, 1982, pp. 12-18.
5. Ames MM, Powis G. Pharmacokinetics of nitrosoureas. In: Ames MM, Powis G, Kovach JS, Editors. Pharmacokinetics of Anticancer Agents in Humans. Netherlands: Elsevier Science Publishers B.V., 1983, pp. 113-134.
6. Ames MM. Pharmacokinetics of antitumor agents in children. In: Ames MM, Powis G, Kovach JS, Editors. Pharmacokinetics of Anticancer Agents in Humans. Netherlands: Elsevier Science Publishers B.V., 1983, pp. 399-431.
7. Ames MM. Metabolism of anticancer drugs in development. In: Powis G, Prough RA, Editors. Metabolism and Action of Anti Cancer Drugs London: Taylor and Francis, 1987, pp. 296-323.
8. Reid JM, Ames MM. Assay methodology. In: Grochow LB, Ames MM, Editors. A Clinician’s Guide to Chemotherapy Pharmacokinetics and Pharmacodynamics. Baltimore: Williams & Wilkins, 1998, pp. 497-514.

1. Ames MM, Lerner P, Lovenberg WM. Modulation of tyrosine hydroxylase activity in the brain. (Abstract 142). 172nd American Chemical Society National Meeting, San Francisco, California, Aug 29-Sept 3, 1976.
2. Ames MM, Melmon KL, Castagnoli N. Studies on the in vivo metabolism of (R) , (S) , and (RS) alpha methyldopa. (Abstract 21). 172nd American Chemical Society National Meeting, San Francisco, California, Aug 29-Sept 3, 1976.
3. Gal J, Ames MM. Gas chromatographic resolution of the enantiomers of DOPA and alpha methyldopa. (Abstract 65). 172nd American Chemical Society National Meeting, San Francisco, California, Aug 29-Sept 3, 1976.
4. Ames MM, Morrissay JJ, Lovenberg W. Characterization of tyrosine hydroxylase in N1E 115 neuroblastoma cell cultures. Fed Proc 36:952, 1977.
5. Powis G, Ames MM. Metabolism of indicine N oxide by the rabbit. Fed Proc 38:444, 1979.
6. Ames MM. Pharmacologic studies of pentamethylmelamine and hexamethylmelamine. Proc Amer Assoc Cancer Res 20:158, 1979.
7. Ames MM, Frank SK. Stereochemical aspects of parachloroamphetamine metabolism. (Abstract 261). Pharmacologist 21:193, 1979.
8. Powis G, Kovach JS, Ames MM. Disposition and effects on divalent cations of L alanosine (ala) in man. Clin Pharmacol Ther 27:282, 1980.
9. Letendre L, Smithson WA, Gilchrist GS, Burgert EO Jr, Hoagland CH, Ames MM, Kovach JS. Activity of a pyrrolizidine alkaloid, indicine N oxide, in refractory acute lymphocytic leukemia. Proc Amer Assoc Cancer Res 21:434, 1980.
10. Kovach JS, Ames MM, Powis G, Lieber MM. Use of a liver microsome system in testing drug sensitivity of tumor cells in soft agar. Proc Amer Assoc Cancer Res 21:257, 1980.
11. Ames MM, Powis G. Metabolism of hexamethylmelamine and pentamethylmelamine by rat liver microsomes and isolated hepatocytes. Proc Amer Assoc Cancer Res 21:257, 1980.
12. Powis G, Creagan ET, Ames MM, Kovach JS. Dose-dependent pharmacokinetic behavior and toxicity of L alanosine in humans. Proc Amer Assoc Cancer Res 21:133, 1980.
13. Ames MM, Dunn LL. Characterization of hexamethylmela¬mine and pentamethylmelamine metabolism by rat liver microsomes and iso¬lated hepatocytes. Pharmacologist 22:215, 1980.
14. Kovach JS, Ames MM, Lieber MM. Pyrrolizidine alkaloid inhibition of colony formation in soft agar by human carcinoma cell lines. (Abstract 1000). Proc Amer Assoc Cancer Res 22:252, 1981.
15. Ames MM, Sanders ME. Metabolic activation of hexamethyl¬melamine and pentamethylmelamine by liver microsomes. (Abstract 103). Proc Amer Assoc Cancer Res 22:26, 1981.
16. Ames, MM, Moertel CG, Moyer TP, Rubin J, Kovach JS. Pharmacology and toxicology of amygdalin (laetrile) in humans. Clin Pharmacol Ther 2:231-232, 1981
17. Ames, Matthew M., Sanders, Mark E. and Tiede, William S. Microsomal metabolism of methylmelamine antitumor agents to alkylating species. The Pharmacologist 23:157, 1981.
18. Sanders ME, Ames MM. Oxidation metabolites of the antitumor agent hexamethylmelamine. Synthesis and characterization of hexamethyl¬melamine 1 oxide. Midwest Regional Meeting, American Chemical Society, Columbia, Missouri, 1981.
19. Ames MM, McGovern R. Antitumor activity of hexamethylmelamine in the human tumor stem cell colony-forming assay is dependent on the presence of a hepatic activating system. (Abstract 469). Pharmacologist 24(3):180, 1982.
20. Ames MM, Miser JS, Coccia P, Smithson WA. Pharmacokinetics of indicine N oxide in pediatric patients. Proc Amer Soc Clin Oncol 1:32, 1982.
21. Ames MM, Sanders ME, Tiede WS. N Methylol¬pentamethylmelamine, an alkylating metabolite of hexamethylmelamine. Proc Amer Assoc Cancer Res 23:1, 1982.
22. Ames MM, Sanders ME, Tiede WS. Hepatic bio¬activation of hexamethylmelamine to the alkylating metabolite N¬ methylolpenta-methylmelamine. 13th International Cancer Congress, Seattle, Washington, Sept 8 15, 1982.
23. Miser JS, Miser AW, Smithson WA, Coccia PF, Ames MM, Davis DM, Hughes CS, Gilchrist GS. A Phase I trial of indicine N oxide in childhood malignancy. (Abstract C-534). Proc Amer Soc Clin Oncol 1:137, 1982.
24. Coffey RJ Jr, Ames MM, Moertel DM, DiMagno EP. Caffeine absorption in the human upper gastrointestinal tract: a model for gastroduodenal drug absorption. Clin Res 30:767A, 1982.
25. Miller Hatch KJ, Ames MM, Gal J. HPLC resolution of chiral amphetamines by derivatization with three chiral reagents. American Chemical Society, Seattle Washington, Mar 20 25, 1983.
26. Ames MM, Miller Hatch KJ, Sanders ME, Gal J, Hurt SD. Synthesis and preparative resolution of tritiated para chloroamphetamine enantiomers. (Abstract MEDI-68). American Chemical Society, Seattle, Washington, Mar 20 25, 1983.
27. Sanders ME, Ames MM, Kovach JS. Chemistry, metabolism and antitumor activity of hexamethylmelamine-1-oxide (HMM-NO). (Abstract MEDI-84) American Chemical Society, Seattle, Washington, Mar 20-25, 1983.
28. Miller Hatch KJ, Ames MM, Kovach JS, Ahmann DL. Cytotoxic activity of hexamethylmelamine (HMM) in human tumor cell lines in the presence of rat hepatic preparations. Proc Amer Assoc Cancer Res 24:247, 1983.
29. Ruud CO, Kovach JS, Sanders ME, Ames MM. Measurement of aminoglutethimide (AG) and N acetylaminoglutethimide (AAG) in biological fluids by high pressure liquid chromatography. Proc Amer Assoc Cancer Res 24:288, 1983.
30. Ames MM, Kovach JS, Rubin J. Pharmacological characterization of Henkel compound (teroxirone, NSC 296934) in animals and humans. Proc Amer Soc Clin Oncol 2:29, 1983.
31. Rubin J, Kovach JS, Moertel CG, Ames MM, Creagan ET, O'Connell MJ. Phase I study of Henkel (HKL) compound on single day and daily for five day schedules. (Abstract C-90). Proc Amer Soc Clin Oncol 2:23, 1983.
32. Miller Hatch KJ, Ames MM, Gal J. HPLC resolution of chiral ring substituted 1 phenyl 2 aminopropanes with four chiral reagents. Minnesota Chromatography Forum, 1983.
33. Miller Hatch KJ, Gretsch S, Ames MM. Sensitive and specific nitrogen gas chromatographic assay for the experimental antitumor agent spirogermanium. Minnesota Chromatography Forum, 1983.
34. Ames MM, Miller Hatch KJ. Metabolic activation of the serotonergic neurotoxin para ¬chloro¬amphetamine by rat liver and rat brain microsomal preparations. Pharmacologist 25:113, 1983.
35. Ames MM, Kovach JS, Rubin J, Moertel DM. Pharmacologic characterization of teroxirone (Henkel compound) in animals and human. 10th International Symposium on the Biological Characterization of Human Tumours, Brighton, England, Oct 24 28, 1983.
36. Ames MM, Sanders ME. Hexamethylmelamine: Metabolic activation and cytotoxicity. 10th International Symposium on the Biological Characterization of Human Tumours, Brighton, England, Oct 24 28, 1983.
37. Ames MM, Miller KJ, Moertel DM. Assay development and preclinical pharmacology of bisbenzimidazole (Pibenzimol.HCl, NSC 322921). Proc Amer Assoc Clin Res 25:297, 1984.
38. Ames MM, Rubin J, Kovach JS. Pharmacologic characteristics of teroxirone, a potent short lived alkylating agent. Intra Arterial and Intracavitary Chemotherapy, San Diego, California, Feb 24 25, 1984.
39. Ames MM, Kovach JS. A parenteral formulation of hexamethylmelamine for use in cancer patients. IUPHAR 9th International Congress of Pharmacology, London, England, July 29 Aug 3, 1984.
40. Ames MM, Kovach JS. Microsomal metabolism and in vitro cytotoxicity of the experimental triepoxide antitumor agent teroxirone. 6th International Symposium on Microsomes and Drug Oxidations, Brighton, England, Aug 5 10, 1984.
41. Miller KJ, Ames MM, Moertel DM. Reversed phase HPLC assay for the experimental antitumor agent bisbenzimidazole (Pibenzimol.HCl, NSC 322921): Preclinical pharmacology and evaluation. Minnesota Chromatography Forum, Spring Symposium, 1984.
42. Miller KJ, Moertel DM, Anderholm DC, Gretsch SK, Ames MM. Preclinical disposition and metabolism studies of pibenzimol (Bisbenzimidazole, NSC 322921). Proc Amer Assoc Cancer Res 26:353, 1985.
43. Richardson RL, Moertel CG, O'Connell MJ, Ames MM, Kovach JS. Phase I study of intravenous hexamethylmelamine (HMM) given on a daily x 5 schedule. (Abstract C-173). Proc Amer Soc Clin Oncol 4:45, 1985.
44. Ames MM, Gretsch SK. DNA DNA and protein-DNA cross-linking by the experimental anticancer agent teroxirone (NSC 296934) in murine L1210 leukemia and human A204 rhabdomyosarcoma cell lines. (Abtract 4273). Fed Proc 44:1141, Mar 5, 1985
45. Miller KJ, Moertel DM, Anderholm DC, Gretsch SK, Ames MM. Preclinical pharmacology studies of the experimental anticancer agent pibenzimol (Bisbenzimidazole, NSC-322921). (Abstract 4272) Fed. Proc 44:1141, Mar 5, 1985.
46. Rubin J, Ames MM, Moertel CG, Creagan ET, O'Connell MJ, Schutt AJ, Kovach, JS. Clinical pharmacologic evaluation of teroxirone on two schedules in patients with advanced solid tumors. 3rd European Conference on Clinical Oncology and Cancer Nursing, Stockholm, Sweden, 1985.
47. Kovach JS, Ames MM, Buck M, Rubin J, Tsukamoto T, Lieber MM. Using the physical, chemical and metabolic characteristics of anticancer agents to advantage in regional chemotherapy. Regional Chemotherapy, Tampa, Florida, Feb 15, 1985.
48. Ames MM, Richardson RL, Kovach JS. Pharmacokinetics of the anticancer agent hexamethylmelamine following intravenous administration of a parenteral formulation. Clin Pharmacol Ther 39:178, 1986.
49. Richardson RL, Ames MM, Kovach JS, Moertel CG. Clinical evaluation of hexamethylmelamine (H) suitable for intravenous administration. Proc Amer Assoc Cancer Res 27:167, 1986.
50. Ames MM, Anderholm DC, Whitfield LR. Assay development and preclinical pharmacology studies with the experimental antitumor agent anthrapyrazole (NSC 349174). Proc Amer Assoc Cancer Res 27:242, 1986.
51. Ames MM, Kovach JS, Moertel CG. Clinical evaluation of hexanethylmelamine (H) suitable for intravenous administration. Proc Am Assoc Cancer Res 27:166, 1986.
52. Ames MM, Kuffel MJ. DNA damage as assessed by alkaline elution in cells incubated with the anthrapyrazole analog oxanthrazole (NSC 349174). Pharmacologist 28:233, 1986.
53. Kinder DH, Ames MM. Synthesis of the boron containing amino acid analog of aspartic acid. American Chemical Society, Anaheim, CA, Sept 9 12, 1986.
54. Kovach JS, Richardson RL, Ames MM. New applications of cisplatinum. Nagaoka International Symposium on Cancer Treatment, Nagaoka, Japan, Oct 16 18, 1986.
55. Frank SK, Mathiesen DA, Kuffel MJ, Szurszewski M, Ames MM. Preclinical pharmacology studies with the anthrapyrazole analog oxantrazole (NSC 349174). Proc Amer Assoc Cancer Res 28:437, 1987.
56. Kinder DH, Frank SK, Ames MM. Preparation of boron and sulfur containing active site directed inhibitors of dehydroorotase (DHO). Proc Amer Assoc Cancer Re. 28:329, 1987.
57. Ames MM, Kuffel MJ, Wieben ED, Kovach JS. Quantitation of human DNA following alkaline elution analysis using the cloned human ‘Alu Sequence’ 32P-labeled probe. Proc Amer Assoc Cancer Res 28:3, 1987.
58. Frank SK, Kinder DH, Ames MM. Boronic acid/ester analogs of carbamyl aspartate as active site directed inhibitors of dihydroorotase. First Symposium of the Protein Society, San Diego, CA, Aug 9 13, 1987.
59. Rubin J, Ames MM, Schutt AJ, Nichols WL, Bowie EJ, Kovach JS. Flavone-8-acetic acid inhibits risstocetin-induced platelet agglutination and prolongs bleeding time. Lancet 2(8567):1081-2, Nov 7, 1987.
60. Ames MM, Kinder DH, Kuffel MJ, Frank SK, Szurszewski M. Cytotoxicity of boron substituted transition state inhibitors of elastase and chymotrypsin against murine and human tumor cells in culture. Proc Amer Assoc Cancer Res 29:336, 1988.
61. Ames MM, Loprinzi CL. Preliminary pharmacologic and toxicologic data from a Phase I clinical trial of oxantrazole incorporating a pharmacologically guided dose escalation scheme. Proc Amer Assoc Cancer Res 29:196, 1988.
62. Ames MM, Mathiesen DA. HPLC assay and preclinical pharmacology of 8 aminoisoindolo[1,2 b]quinazolin 12(010h)-one, Bayer 2049 (NSC 320846). Proc Amer Assoc Cancer Res 29:506, 1988.
63. Ames MM, Reid JM, Pendergass TW, Hammond D. Pharmacokinetics of idarubicin and idarubicinol following daily x 3 or weekly x 3 administration to children with leukemia in second or subsequent marrow relapse. Proc Amer Assoc Cancer Res 29:196, 1988.
64. Ames MM, Rubin J, Svingen PA, Nichols WL, Bowie EJW, Fitch TR, Schutt AJ, Kovach JS. Clinical pharmacologic studies of flavone-8-acetic acid (FAA). Proc Amer Soc Cli. Oncol 7:60, 1988.
65. Loprinzi C, Hartmann L, Ames, M. Cyclophosphamide, methotrexate, and 5 fluorouracil (CMF) associated ocular toxicity. Clin Res 36:479A, 1988.
66. Kueker MJ, Kuffel MJ, Frank SK, Kinder DH, Ames MM. Enzyme inhibition, in vitro cytotoxicity and cellular effects of novel boron containing serine protease inhibitors. Proc Amer Assoc Cancer Res 30:563, 1989.
67. Mathiesen DA, Reid JM, Ames MM. Potential relationship between the species specific toxicology and preclinical pharmacology of batracylin in mice and rats. Proc Amer Assoc Cancer Res 30:541, 1989.
68. Reid JM, Kuffel MJ, Pendergrass TW, Hammond D, Ames MM. Cytotoxic concentrations of idarubicinol, the alcohol metabolite of idarubicin, are present in CSF following administration of idarubicin to children with relapsed leukemia. Proc Amer Assoc Cancer Res 30:250, 1989.
69. Reid JM, Mathiesen DA, Ames MM. HPLC assay and preclinical pharmacology of 3,5 dichloro 2,4-dimethoxy-6-(trichloromethyl) pyridine, penclomidine (NSC-338720). Proc Amer Assoc Cancer Res 30:540, 1989.
70. Reid JM, Mathiesen DA Ames MM. Preclinical evaluation of the disposition and metabolism of 3,5-dichloro-2,4-dimethoxy-6-(trichloromethyl)pyridine, penclomedine (NSC-338720). Pharmacologist 31:155, 1989.
71. Kinder DH, Elstad CA, Meadows GG, Ames MM. In vivo activity of boro-amino acid analog chymotrypsin and elastase inhibitors against B16-BL6 melanoma. Proc Amer Assoc Cancer Res 31:411, 1990.
72. Kuffel MJ, Reid JM, Ames MM. Characterization of cytotoxicity and DNA damage of idarubicin (ID), idarubicinol (IDOL) and related anthracyclines and their alcohol metabolites following incubation with human leukemia cells. Proc Amer Assoc Cancer Res 31:399, 1990.
73. Mruk JS, Chesebro JH, Webster MWI, Grill DE, Rubin J, Ames MM., Reid JM, Kovach JS. Flavone acetic acid reduces platelet-thrombosis and vasoconstriction after arterial injury in vivo. Circulation 82(Suppl.):III-768, 1990.
74. Reid JM, Benson JW, Ames MM. Preclinical pharmacology of morpholinyldoxorubicin (NSC-354646, MDX) and cyanomorpholinyldoxorubicin (NSC-357704, CMDX) in mice. Proc Amer Assoc Cancer Res 31:386, 1990.
75. Reid JM, Mathiesen DA, Benson LM, Ames MM. Murine pharmacology of 3,5-dichloro-2,4-dimethoxy-6-trichloro-[14C]-methylpyridine (NSC 338720, 14C-penclomedine, PEN). Proc Amer Assoc Cancer Res 31:386, 1990.
76. Wick MJ, Kinder DH, Salisbury JL, Sanders MA, Ames MM. Cellular characterization of cytotoxic mechanism-based serine protease inhibitors. Pharmacologist 32:157, 1990.
77. van Haelst-Pisani C, Loprinzi, CL, Ames MM, Collins JM, Richardson RL, Moertel CG. Phase I clinical trial of pirozantrone hydrochloride (Pz). Proc Amer Assoc Cancer Res 31:199, 1990.
78. Ames MM, Kinder DH, Wick MJ. Mechanism-based serine protease inhibitors as potential antitumor agents: cellular targets. J Cell. Biochem Suppl. 15G:139, 1991.
79. Ames MM, Reid JM, Kuffel MJ, Pendergrass TW, Krail MD, Hammond GD. Biochemical and clinical pharmacology of idarubicin. 5th International Symposium on Therapy of Acute Leukemias, Roma, Italy, Nov 1-6, 1991, Haematologica 76:10, 1991.
80. Benson JW, Reid JM, Ames MM. ELISA assay and preclinical pharmacology of cholera toxin. Proc Amer Assoc Cancer Res 32:386, 1991.
81. Gilbert JA, Kvols LK, Ames MM. Characterization of tryptophan hydroxylase and aromatic-L-amino acid decarboxylase in carcinoid tumor tissue. Proc Amer Assoc Cancer Res 32:11, 1991.
82. Reid JM, Sensenbaugh KR, Benson JW, Ames MM. HPLC assay and preclinical pharmacology of 9-methoxy-N-2-methylellipticinium acetate (NSC-627505). Proc Amer Assoc Cancer Res 32:347, 1991.
83. Wick MJ, Kinder DH, Ames MM. Potential targets of cytotoxic serine protease inhibitors in tumor cells. Proc Amer Assoc Cancer Res 32:11, 1991.
84. Hartmann L, Ames M, Reid J, Richardson R, Burnham N, Piens,J. Limiting myelosuppression with diaziquone (AZQ), despite GM-CSF, in a Phase I study. Proc Amer Soc Clin Oncol 11:128, 1992.
85. Cole D, Blaney S, Balls F, Reaman G, Craig C, Feusner J, Dinndorf P, Krailo M, Ames M, Hammond D, Poplack D. A Phase I and pharmacokinetic study of topotecan in pediatric patients. Proc Amer Soc Clin Oncol 11:116, 1992.
86. Reid JM, Burch PA, Benson LM, Gilbert JA, Richardson RL, Ames MM. Phase I clinical and pharmacologic evaluation of topotecan administered by a 24 hour continuous infusion. Proc Amer Assoc Cancer Res 33:259, 1992.
87. Wick MJ, Zembower DE, Millikan RE, Ames MM. Intracellular tumor cell targets of cytotoxic serine protease inhibitors. Proc Amer Assoc Cancer Res 33:20, 1992.
88. Reid JM, O'Connell MJ, Conley BA, Reischman B, Therneau TM, Ames MM. Pharmacokinetic and toxicologic assessments of doxorubicin dose reductions in patients with elevations in total bilirubin. Proc Amer Assoc Cancer Res 33:256, 1992.
89. Reid JM, Benson JW, Benson LW, Kuffel MJ, Ames MM. In vitro metabolic activation and metabolism of penclomedine (NSC-338720). Proc Amer Assoc Cancer Res 33:510, 1992.
90. Ames MM, Reid JM, Feig SA, Gerber MC, Kuffel MJ, Wick MJ. Recent clinical pharmacology and biochemical studies of idarubicin. 24th Congress of the International Society of Haematology, South Bank Centre, London, United Kingdom, Aug 23-27, 1992.
91. Zembower DE, Gilbert JA, Ames MM. Enantiospecific syntheses of ª-(S)-fluoromethyltryptophan and ª-(S)-fluoromethyl-5-hydroxytryptophan. (#214 & #488) 203rd American Chemical Society National Meeting, San Francisco, CA, April 5-10, 1992.
92. Haddock MG, Bonner JA, Ames MM. Analysis of the interaction of radiation and the topoisomerase II reactive drugs etoposide and idarubicin. Radiation Research Society, 41st Annual Meeting, 1992.
93. Ames MM, Bagniewski PG, Reid JM, Richardson RL, Marks RS, Letendre L, Tefferi A. Clinical and pharmacokinetic evaluation of 2-chloro-deoxyadenosine: results from three Phase I clinical trials. Proc Amer Assoc Cancer Res 34:394, 1993.
94. Walker DL, Reid JM, Ames MM. Preclinical pharmacology of bizelesin (NSC-615291): A potent bifunctional analog of CC-1065 and adozelesin. Proc Amer Assoc Cancer Res 34:376, 1993
95. Reid JM, Berg S, Ames MM, Balis FM, Poplack DG, Feig S, Kuffel MJ, Hammond D. Cerebrospinal fluid pharmacokinetics of idarubicin and idarubicinol. Proc Amer Assoc Cancer Res 34:394, 1993.
96. Seibel N, Ames M, Ivy P, Krailo M, Reaman G, Reid J, Kent P, Hammond D. Phase I study of taxol in refractory leukemia in children. Proc Amer Soc Clin Oncol 12:145, 1993.
97. Mahlum CE, Reid JM, Ames MM. Metabolic activation of penclomedine. Seventh National Conference on Undergraduate Research, University of Utah, 1993.
98. Reid JM, Bagniewski PG, O'Connell RJ, Mosher M, Kovach JS, Ames MM. Reverse phase HPLC assays for p-hydroxylevamisole and 1-(2-mercaptoethyl)-4-phenyl-2-imidazolindinone, pharmacologically active metabolites of levamisole. Minnesota Chromatography Forum, Bloomington, MN, May 4-5, 1993.
99. Reaman GH, Ames MM, Seibel N, Sato J, Avramis VI, Madden T, Bleyer WA. Clinical pharmacology and new agent trials: Childrens Cancer Group. 6th Pharmacology Workshop Satellite to XXV SIOP Meeting, The Role of Clinical Pharmacology in Pediatric Oncology (Riccardi, R. and Borsi, J., Editors), San Francisco, CA, pp. 65-72, October 5, 1993.
100. Gilbert JA, Bates LA, Ames MM. Kinetics of tryptophan hydroxylase and aromatic-L-amino acid decarboxylase in human carcinoid tumors. Soc. Neurosci. 19:1557, 1993.
101. Lorenzo NY, Ames MM, Windebank AJ. Dissociation of cis-platinum induced neurotoxicity and chemotherapeutic efficacy. Soc. Neurosci. 19:1482, 1993.
102. Tefferi A, Witzig TE, Reid JM, Li CY, Ames, MM. A Phase I study of combined 2-chlorodeoxyadenosine and chlorambucil in chronic lymphoid leukemia and low grade lymphoma. Blood 82(Suppl. 1):580A, 1993.
103. Zembower DE, Ames MM. Synthesis of 5-(Alkyl and Aryl)-L-Tryptophan Analogues Via Palladium-Catalyzed Cross-Coupling. (#68) 207th American Chemical Society National Meeting, San Diego, CA, March 13-17, 1994.
104. Zembower DE, Neudauer CL, Wick MJ, Ames MM. Peptide Boronic Acids. Versatile Synthetic Ligands for Highly Specific Affinity Chromatography of Serine Proteinases. (#46) 207th American Chemical Society National Meeting, San Diego, CA, March 13-17, 1994.
105. Neudauer CL, Wick MJ, Zembower DE, Ames MM. Boronic Acid Containing Serine Protease Inhibitors as Potential Antitumor Agents: Isolation of Target Proteins by Affinity Chromatography. Proc Amer Assoc Cancer Res 35:69, 1994.
106. Reid JM, Walker DL, Naylor S, Benson LM, Ames MM. Murine Metabolism of Pyrazoloacridine (NSC-366140): Identification and Cytotoxicity of the Urinary Metabolites 9-Desmethyl Pyrazoloacridine and Pyrazoloacridine N-oxide. Proc Amer Assoc Cancer Res 35:421, 1994.
107. Walker DL, Reid JM, Ames MM. Preclinical Pharmacology of the Potent Marine Natural Product, Ecteinascidin 729 (NSC-638718). Proc Amer Assoc Cancer Res 35:421, 1994.
108. Kuffel MJ, Ames MM. Carbonyl Reductase Conversion of Idarubicin to Idarubicinol in Human Liver and Brain Preparations. Proc Amer Assoc Cancer Res 35:421, 1994.
109. Dhodapkar M, Reid J, Ames MM, Buckner JC, Burch PA, Rubin J. Phase I Clinical Trial and Pharmacokinetics of Temozolamide (NSC 362856). Proc Amer Assoc Cancer Res 35:245, 1994.
110. Reid JM, Bagniewski PG, Richardson RL, Marks RS, Letendre L, Tefferi A, Ames MM. Clinical Pharmacology of 2-Chlorodeoxyadenosine in Patients with Solid Tumors, Chronic Leukemia or Lymphoma. 8th NCI-EORTC Symposium, , Amsterdam, The Netherlands, page 174, March 15-18, 1994
111. Seibel N, Ames M, Ivy P, Krailo M, Reid J, Kent P, Reaman G. Phase I and Pharmacologic Study of Paclitaxel in Refractory Pediatric Leukemias: A Childrens Cancer Group Study. Proc Amer Soc Clin Oncol 13:324, 1994.
112. Benson LM, Tomlinson AJ, Walker DL, Reid JM, Ames MM, Naylor S. Study of the Metabolism of the Antitumor Drug Pyrazoloacridine by CE-MS Using Nonaqueous CE Run Media. American Society of Mass Spectrometry, Chicago, IL, May 29-June 3, 1994.
113. Hartmann LC, Marks RS, Loprinzi CL, Ingle JN, Reid JM, Ames MM. Phase II trial of suramin in advanced breast cancer. Inter Cancer Res Symp, Oct. 20-21, 1994.
114. Feig SA, Harris RE, Ames M, Steinherz L, Sather H. Idarubicin (IDR) Vs Daunorubicin (DNR) in Treatment of Childhood Acute Lymphoblastic Leukemia (ALL) After First Bone Marrow Relapse. ISEH, 1995.
115. Ames MM, Reid JM, Stevens DG, Rhodes WL, Nicholson S, Reaman G. Temozolomide (TEM) pharmacokinetics in the Childrens Cancer Group Phase I trial of TEM administered as a single oral dose on a daily x 5 schedule. Proc Amer Assoc Cancer Res 36:236, 1995.
116. Reid JM, Walker DL, Ames MM. Evaluation of an L1210 bioassay and HPLC for determination of dolastatin 10 in human and murine plasma. Proc Amer Assoc Cancer Res 36:364, 1995.
117. Stevens DG, Reid JM, Rhodes WL, Rubin J, Ames MM. Pharmacokinetics of MTIC and other temozolomide (TEM) metabolites following administration of TEM to patients with advanced cancer. Proc Amer Assoc Cancer Res 36:364, 1995.
118. Walker DL, Reid JM, Ames MM. Preclinical pharmacology of the HIV protease inhibitor, DG35 (NSC 654021). Proc Amer Assoc Cancer Res 36:364, 1995.
119. Nicholson HS, Ames MM, Reid JM, Krailo M, Renick-Ettinger A, Seibel NL, Reaman GH. Phase I pharmacokinetic study of temozolomide (TEM) in children and adolescents. A report from the Children's Cancer Group (CCG). Proc Am Soc Clin Oncol 14:449, 1995.
120. Reid JM, Walker DL, Naylor S, Benson LM, LoRusso PM, Ames MM. Identification of metabolites of pyrazoloacridine (NSC-366140) in mouse and human urine by HPLC and capillary electrophoresis-electrospray ionization mass spectrometry. Sixth International Symposium on Pharmaceutical and Biomedical Analysis, St. Louis, MO, April 23-26, 1995.
121. Zembower DE, Kuffel MJ, Ames MM. Inhibition of human topoisomerase II by cytotoxic 4,7-indolequinones, synthesis and structure-activity relationships. American Chemical Society, Anaheim, CA, April 2-6, 1995.
122. Bleyer WA, Krailo M, Ames M, Avramis V, Madden T, Blazar B, Cairo M, Sato J, Seibel N, Reaman G. Clinical pharmacology of new agents: Childrens Cancer Group (CCG) studies in the 1990s. Japan-U.S. Symposium on Pediatric Cancer, Nagoya, Japan, March 26-28, 1995
123. Ames MM. Idarubicin: Basic and clinical pharmacology. VI. International Conference on Malignant Lymphoma, Lugano, Switzerland, June 5-8, 1996.
124. Pitot HC, Erlichman C, Goldberg RM, Reid JM, Ames MM, Schaaf LJ, Dietz AJ. Phase I trial of irinotecan (CPT-11) given once every three weeks to patients with advanced solid tumors. Proc Amer Soc Clin Oncol 15:494, 1996.
125. Neudauer CL., Zembower DE, Briden AL, Wick MJ, Ames MM. Characterization of the tumor cell target proteins of a peptide boronic acid serine protease inhibitor: evidence for identity with human lysosomal protective protein. Proteases and Protease Inhibitors: Amer Assoc Cancer Res, March, 1996.
126. Bagniewski PG, Reid JM, Ames MM, Bonner JA, Buckner JC, Sloan JA. Increased etoposide clearance in patients with glioma may be associated with concurrent glucocorticoid or anticonvulsant treatment. Proc Amer Assoc Cancer Res 37:179, 1996.
127. Ames MM, Walker DL, Reid JM, Svingen PA, Budihardjo I, Kaufmann SH, Covey JM, Alley MC, Hollingshead MG. 6-Aminonicotinamide: murine plasma pharmacokinetics and modulation of drug resistance. Proc Amer Assoc Cancer Res 37:289, 1996.
128. Neudauer CL, Ames MM. Tumor cell target proteins of a peptide boronic acid serine protease inhibitor. Probable identification and characterization of a chymotrypsin-like endopeptidase activity. Proc Amer Assoc Cancer Res 37:91, 1996.
129. Goldberg RM, Reid JM, Ames MM, Sloan JA, Rubin J, Erlichman C, Kuffel MJ, Fitch TR. Phase I clinical trial and pharmacokinetics of fazarabine. Proc Amer Assoc Cancer Res 37:164, 1996.
130. Alberts SR, Erlichman C, Reid JM, Ames MM, Sloan JA, Richardson RL. Phase I trial of KW2189 in solid tumors using a 5-day administration schedule. Proc Amer Assoc Cancer Res 37:393, 1996.
131. Gilbert JA, Frederick LM, Ames MM. Increased levels of aromatic-L-amino acid decarboxylase protein and mRNA in human carcinoid tumors. Society of Neuroscience, 22(1-3):603, 1996.
132. Kuffel MJ, Reid JM, Ames MM. Cytochrome P450 catalyzed metabolism of Ecteinascidin 743 by rat and human liver microsomes. Proc Amer Assoc Cancer Res 38:596, 1997.
133. Reid JM, Miller JK, Blajeski AL, Ames MM. Identification of human liver microsoml enzymes that catalyze the N-oxidation and N- and O-demethylation of pyrazoloacridine. Proc Amer Assoc Cancer Res 38:595, 1997.
134. Neudauer C., Lau JS, Ames MM. Cathepsin A is a tumor cell target protein of a cytotoxic peptide boronic acid serine protease inhibitor. Proc Amer Assoc Cancer Res 38:562, 1997.
135. Safgren SL, Reid JM, Buckner JC, Rajkumar SV, Rios R, Ames MM. HPLC method for and preliminary pharmacokinetics of the reactive metabolites of dacarbazine. Proc Amer Assoc Cancer Res 38:600, 1997.
136. Bagniewski .G, Reid JM, Pitot HC, Sloan JA, Ames MM. Pharmacokinetics of Dolastatin 10 in adult patients with solid tumors. Proc. Amer. Assoc. Cancer Res. 38:221-222, 1997.
137. Nicholson HS, Krailo M, Seibel NL, Ames MM, Renick-Ettinger A, Reaman GH. Phase I study of temozolomide (TEM) in children and adolescents. A report from the Children's Cancer Group (CCG). Proc Amer Assoc Clin Oncol, 1997.
138. McElroy EA Jr, Pitot HC, Erlichman C, Reid JM, Ames MM, Windebank AJ, Sloan JA, Rubin J. Phase I trial of Dolastatin-10 in patients with advanced solid tumors. Proc Amer Assoc Clin Oncol 16:233A, 1997.
139. Gilbert JA, Frederick LM, Ames MM. High expression of aromatic-L-amino acid decarboxylase in carcinoid primary and metastatic tumors. Proc. Amer Assoc Cancer Res 39:480, 1998.
140. Safgren SL, Reid JM, Buckner JC, Rajkumar SV, Rios R, Ames MM. Pharmacokinetics of dacarbazine and its active metabolites MTIC and HMMTIC in patients with recurrent glioma. Proc Amer Assoc Cancer Res 39:327, 1998.
141. Kuffel MJ, Reid JM, Squillace DP, Ames MM. Cytochrome P450 and 17ß-hydroxysteroid dehydrogenase oxidation of 2-methoxyestradiol by murine and human hepatic microsomes. Proc Amer Assoc Cancer Res 39:524, 1998.
142. Squillace DP, Reid JM, Kuffel MJ, Ames MM. Bioavailability and in vivo metabolism of 2-methoxyestradiol in mice. Proc Amer Assoc Cancer Res 39:523, 1998.
143. Galanis E, Goldberg RM, Erlichman C, Rubin J, Pitot HC, Adjei AA, Alberts SR, Burch PA, Reid JM, Safgren SL, Witzig TE, Sloan JA, Ames MM. Phase I trial of sequential administration of tomudex and 5-iodo-2’-deoxyuridine (IdUrd). Proc Amer Assoc Cancer Res 39:321, 1998.
144. Reid JM, Kuffel MJ, Squillace DP, Ames MM. Characterization of the in vitro metabolism, pharmacokinetics, and biliary excretion of Ecteinascidin 743 (NSC 648766) in male and female rats. (#191) Ann Oncol 9(Suppl 2):50, 1998.
145. Rajkumar SV, Buckner JC, Schomberg PJ, Reid JM, Bagniewski PJ, Ames MM, Cascino TL, Marks RS. Phase I and pharmacokinetic (PK) study of pre-irradiation chemotherapy (CP) with BCNU, cisplatin, oral etoposide and accelerated hyperfractionated radiation therapy (AXRT) in high grade glioma. Proc Amer Soc Clin Oncol 17:386a, 1998.
146. Frangoul H, Ames MM, Reid JM, Krailo M, Seibel N, Steinherz P, Whitlock J, Holcenberg J. Phase I study of topotecan administered as a 21-day continuous infusion in children with recurrent solid tumors. A report from the Children's Cancer Group (CCG). Proc Amer Soc Clin Oncol 17:188a, 1998.
147. Kuffel MJ, Squillace DP, Reid JM, Ames MM. Cytochrome P450-catalyzed metabolism of the aminoflavone analog NSC 686288 in human and rat liver microsomes: the role of CYP1A subfamily enzymes. Proc Amer Assoc Cancer Res 40:384, 1999.
148. Bagniewski PG, Reid JM, Villablanca JG, Reynolds CP, Ames MM. A phase I pharmacokinetic study of Fenretinide (HPR) in children with high-risk solid tumors. A Childrens Cancer Group (CCG) Study. Proc. Amer. Assoc. Cancer Res. 40:92, 1999.
149. Pitot HC IV, Erlichman C, Reid JM, Sloan JA, Ames MM, Bagniewski PG, Atherton-Skaff P, Adjei AA, Rubin J, Rayson D, Goldberg RM. A phase I study of bizelesin (NSC 615291) in solid tumors. Proc Amer Assoc Cancer Res 40:91-92, 1999.
150. Galanis E, Goldberg R, Erlichman C, Sloan J, Reid J, Pitot H, Rubin J, Alberts S, Adjei A, Safgren S, Atherton-Skaff P, Witzig T, Ames M. Phase I trial of sequential administration of tomudex and 5-iodo-2’-deoxyuridine (IdUrd). Proc Am Soc Clin Oncol. 18:172a, 1999.
151. Gilbert JA, Frederick LM, Ames MM. Cytotoxicity of carbidopa, an inhibitor of aromatic-L-amino acid decarboxylase, to human pulmonary carcinoid and small cell lung carcinoma cells. Society of Neurosciences 25(1-2):177, 1999.
152. Frederick LM, Gilbert JA, Ames MM. Studies of the mechanism by which aromatic-L-amino acid decarboxylase inhibitors induce carcinoid tumor cell death. Society of Neurosciences 25(1-2):177, 1999.
153. Safgren SL, Holcenberg JS, Steinherz PG, Reid JM, Seibel NL, Reaman GH, Ames MM. Gemcitabine pharmacokinetics in pediatric patients with solid tumors, leukemia and non-Hodgkin’s lymphoma: A Children’s Cancer Group Study. Proc Amer Assoc Cancer Res 41:416-417, 2000.
154. Squillace DP, Ruben SL., Reid, J.M. and Ames, M.M. HPLC analysis and murine pharmacokinetics of the cytotoxic bioreductive agent NLCQ-1 (NSC 709257). Proc Amer Assoc Cancer Res 41:706, 2000.
155. Kuffel MJ, Bowman SL, Browne JA, Reid JM, Naylor S, Ames MM. Tumor cell- and tissue-selective cytochromes P450 oxidation of aminoflavone analog NSC 686288 (AF). Proc Amer Assoc Cancer Res 41:370, 2000.
156. Salazar S, Reid J, Erlichman C, Ames M. HPLC assay development and clinical pharmacology of the antitumor agent 17-allylaminogeldanamycin in cancer patients. 7th Biennial Symposium on Minorities, the Medically Underserved & Cancer, 2000.
157. Erlichman C, Toft D, Reid J, Sloan J, Atherton P, Adjei A, Ames M, Croghan G. A Phase I trial of 17-allyl-amino-geldanamycin in patients with advanced cancer. Proc Amer Assoc Cancer Res 42:833, 2001.
158. Erlichman C, Boerner S, Hallgren C, Stensgard B, Spieker R, Ames M, Toft D. Effect of geldanamycin on HSP90 cochaperone proteins. NCI-EORTC-AACR Symposium, Amsterdam, Nov 9, 2000.
159. Mehta MP, Forouzannia A, Ames M, Reid J, Vezina G, Kuttesch J, LaFond D, Pollack I, Reaman G, Shaw D, Timmerman R, Krailo M. Phase I study of motexafin-gadolinium (M-Gd) as a radiosensitizer for pediatric intrinsic pontine glioma (BSG): a Children's Oncology Group Study. Proc Amer Soc Clin Oncol 20:62a, 2001.
160. Pitot HC, Adjei AA, Reid JM, Sloan JA, Goldberg RM, Rubin J, Alberts SR, Duncan BA, Eli MP, Schaaf LJ, Knight RD, Archinal AE, Miller LL, Erlichman C. A Phase I and pharmacokinetic study of a powder-filled capsule (PFC) formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors. Proc Amer Soc Clin Oncol 20:102a, 2001.
161. Reid JM, Adjei A, Sloan J, Diasio R, Smith DA, Pitot H, Rubin J, Alberts S, Goldberg R, Hanson L, Atherton P, Ames M, Erlichman C. A comparative pharmacokinetic study of continuous venous infusion (CVI) 5-fluorouracil and oral 5-fluorouracil with the dihydropyrimidine dehydrogenase (DPD) inactivator eniluracil in patients with advanced solid tumors. Proc Am Soc Clin Oncol 20:90a, 2001.
162. Ames M, Schroeder JC, Pobst LJ, Kuffel MJ, Arnt CR. Aminoflavone (NSC 686288) induction of cytochrome P450 1A1 in sensitive human tumor cell lines is associated with metabolic activation, DNA damage and antiproliferative activity. Clin Cancer Res 7:3797s, 2001.
163. Longenbach-Huber S, Safgren S, Raich T, George J, Ames M, O'Kane DJ. Cytochrome P450 (CYP450) genotyping on the CodelinkTM Bioarray. AACC 2001, San Diego, CA, Nov 8-9, 2001.
164. Bolterman SA, Reid JM, Covey JM, Alley MC, Waxman S, Ames MM. Murine pharmacokinetics of the potent differentiating dithiophene dione analogs NSC 682994 and NSC 656240. Proc Amer Assoc Cancer Res 43:78, 2002.
165. Qu G, Croghan GM, Conover C, Erlichman C, Reid JM, Burch PA, Sloan JA, Pitot HC, Hanson LJ, Atherton P, Ames MM, Adjei AA. A Phase I and pharmacologic study of suramin with sequential adriamycin in patients with advanced solid tumors. Proc Amer Assoc Cancer Res 43:80, 2002.
166. Reid JM, Bolterman SA, Bagniewski P, Ames MM. Pharmacokinetics of safingol and fenretinide in rats. Proc Amer Assoc Cancer Res 43:427, 2002.
167. Villablanca JG, Ames MM, Reid JM, Bagniewski P, Krailo M, Reynolds CP. Children's Cancer Group Phase I trial of oral [N-(4-hydroxyphenyl) retinamide] (4-HPR) in children with resistant/recurrent solid tumors (CCG 09709). Proc Amer Soc Clin Oncol 21:398a, 2002.
168. Pitot HC, Frytak S, Croghan GA, Hillman DW, Reid JM, Ames MM, Richardson RL, Moynihan TJ, Windebank AJ, Burch PA. Phase II study of dolastatin-10 (dola-10) in patients (pts) with advanced renal cell carcinoma. Proc Amer Soc Clin Oncol 21:149b, 2002.
169. Bolterman SA, Reid JM, Shami PJ, Ames MM. HPLC analysis of the NO-donating prodrug JS-K: Inhibition of sulfhydryl-catalyzed degradation in plasma and whole blood lysates by thiol depletion with diamide. Proc Amer Assoc Cancer Res 44:387, 2003.
170. Reid JM, Bolterman SA, Kuffel MJ, Ames MM. Pharmacokinetics and metabolism of the selective Ah receptor modulatro 6-MCDF in mice and rats. Proc Amer Assoc Cancer Re. 44:161, 2003.
171. Jia L, Spanswick VJ, Reid JM, Kuffel M, Buhrow SA, Ames MM, Hartley JA, Thurston DE, Tomaszewski JE. Use of the Comet assay as a surrogate biomarker for the in vivo measurement of DNA damage to lymphocytes. Proc Amer Assoc Cancer Res 45:452, 2004.
172. Jia L, Peggins J, Reid JM, Buhrow SA, Ames MM, Kobs DJ, Grossi IM, Thurston DE, Tomaszewski JE. Interspecies differences in pharmacokinetics and time-dissociated toxicokinetics of SJG-136. Proc Amer Assoc Cancer Res 45:487, 2004
173. Reid JM, Buhrow SA, Kuffel MJ, Jia L, Covey JM, Ames MM. LC-MS/MS assay and rat pharmacokinetics and metabolism of the dimeric pyrrolobenzodiazepine SJG-136. Proc Amer Assoc Cancer Res 45:1248, 2004
174. Gilbert JA, Baer J, Eckloff B, Weiben E, Ames M, Weinshilboum R. Gemcitabine pharmacogenetics: cytidine deaminase and deoxycytidylate deaminase genotype-to-phenotype studies. Proc Amer Assoc Cancer Res 45:1096, 2004
175. Goetz MP, Jatoi A, Geyer SM, Safgren SL, Kuffel MJ, Adjei AA, Castillo RA, Dakhil SR, Fitch TR, Ames MM. MDR1 and CYP3A5 polymorphisms and clinical outcome in elderly patients treated with oral Vinorelbine as first-line therapy for metastatic non-small cell lung cancer. Proc Amer Assoc Cancer Res 45:1097, 2004.
176. Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, Flockhart DA, Adjei AA, Weinshilboum RM, Couch FJ, Lingle W, Desta Z, Perez EA, Ingle JN. Pharmacogenomic determinants of outcome with tamoxifen therapy: findings from the randomized North Central Cancer Treatment Group adjuvant breast cancer trial 89-30-52 9Abstract 314) Breast Cancer Res Treat 88(Suppl 1):S35, 2004.
177. Gilbert JA, Safgren SL, Lloyd RV, Ames MM. Gastrointestinal neuroendocrine tumors lack epidermal growth factor receptor mutations predictive of gefitinib response. Proc Am Assoc Cancer Res 46:974, 2005.
178. Reid JM, Goetz MP, Rao RD, Safgren SL, McGovern RM, Furth AF, Felten SJ, Mandrekar SJ, Adjei AA, Erlichman C, Pitot HC, Ames MM. Relationships between irinotecan pharmacokinetics and UGT1A1 AND MDR1 polymorphisms in a Phase I trial of irinotecan and erlotinib. Proc Am Assoc Cancer Res 46:975, 2005.
179. Kuffel MJ, Buhrow SA, Reid JM, Jia L, Ames MM. Kynurenine: a biomarker for in vitro and in vivo modulation of indoleamine 2,3-dioxygenase by 1-Methyl-[D]-tryptophan (NSC 721782). Proc Am Assoc Cancer Res 46:982, 2005.
180. Buhrow SA, Reid JM, Jia L, Shoji M, Snyder JP, Liotta DC, Ames MM. LC/MS/MS assay and mouse pharmacokinetics and metabolism of the novel curcumin analog EF-24 (NSC 716993). Proc Am Assoc Cancer Res 46:984, 2005.
181. Jia L, Kuffel MJ, Buhrow SA, Reid JM, Ames MM. Pharmacokinetic profile 1-methyl-[d]-tryptophan, an orally-bioavailable immune modulator. Proc Am Assoc Cancer Res 46:987, 2005.
182. Whitlock JA, Krailo M, Reid JM, Ruben SL, Ames MM, Owen W, Reaman GH. Phase I clinical and pharmacokinetic study of flavopiridol in children with refractory solid tumors: a children’s oncology group study. Proc Am Assoc Cancer Res 46:1117, 2005.
183. Schroeder JC, Kuffel MJ, Ames MM. Effects of manipulating human tumor cell line expression of CYP1A1 on metabolic activation of and sensitivity to aminoflavone. Proc Am Assoc Cancer Res 46:1175, 2005.
184. Erlichman C, Adjei AA, Joy ME, Rubin SD, Friedman RA, Ames MM, Reid JM, Mandrekar S, Felten S, Molina JR. A Phase I Study of lapatinib (GW572016) and topotecan in patients with solid tumors. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Philadelphia, PA, November, 2005.
185. Rumilla KM, Zhand H, Erickson LA, Hobday TJ, Rubin J, Erlichman C, Ames MM, Lloyd RV. RASSF1A expression and gene methylation in ileal carcinoid tumors (Abstract 546). Mod Pathol 18(Suppl 1):117A 2005.
186. Goetz MP, Safgren S, Goldberg RM, Grothey AF, Mandrekar SJ, Reid JM, Erlichman C, Adjei AA, Rubin J, Ames MM. A phase I dose escalation study of irinotecan (CPT-11), oxaliplatin (Oxal), and capecitabine (Cap) within three UGT1A1 promoter cohorts (6/6, 6/7, and 7/7) (Abstract 2014). J Clin Oncol (16S part 1):138s, June 23, 2005.
187. Furth AF, Mandrekar SJ, Rau A, Reid JM, Tan A, Felten SJ, Erlichman C, Ames MM, Adjei AA. A regression based approach for developing a limited sample model for pharmacokinetic data. Spring Meeting of Eastern North American Region (ENAR) of the International Biometric Society (IBS), 2006.
188. Kuffel MJ, Buhrow SA, Myers RM, Greiner SM, Harvey ME, Reid JM, Peng KW, Federspiel MJ, Jia L, Russell SJ, Ames MM. Tissue distribution of viral gene expression after intravenous administration of an oncolytic measles virus encoding the sodium-iodide symporter (MV-NIS) in transgenic IfnarKO x CD46 Ge mice. Proc Amer Assoc Cancer Res 47:#2093, Aprl, 2006.
189. Bradley K, Mehta M, Adamson P, Ames M, Jakacki R, Vezina G, Ingle A, Ivy P, Blaney S, Pollack I. Phase I study of concurrent motexafin gadolinium (MGd) with radiation therapy for children with newly diagnosed brain stem gliomas (BSG): a Children’s Oncology Graoup study (#9014) J Clin Oncol 24(Suppl 18S):505s, June, 2006.
190. Gilbert JA, Goetz MP, Giordano KF, Reynolds CA, Ingle JN, Lingle WL, Adjei AA, Ames MM. Mutational analysis of the epidermal growth factor receptor and stem cell factor receptor genes in metaplastic breast carcinoma (Abstract 3025). Breast Cancer 100(Suppl 1):S132-3, 2006.
191. Goetz MP, Suman V, Couch F, Ames M, Rae J, Erlander M, Knox S, Ma X.J, Reynolds C, Visscher D, Lingle W, Flockhart D, Desta Z, Sgroi D, Goss P, Perez E, Ingle J. An index based on HOXB13/IL17BR and CYP2D6 for determination of relapse and survival in tamoxifen-treated node negative breast cancer. Breast Cancer Res Treat 100(Suppl 1):S53, 2006.
192. Audriani M, Buchanan ML, Easterling T, Kaplan H, Carr D, Berg S, Scorsone K, Ames M, Reid J, Petros W, McManus T, Reed E, Shen D, Swisher E, Skolnik J, Hebert MF. Pharmacokinetics of Chemotherapy in Pregnancy and Lactation: An OPRU Network Study. 2007 Annual Meeting of the American College of Clinical Pharmacy, October 14-17, 2007.
193. Dispenzieri A, Myers RM, Tong C, Greiner SM, Harvey ME, Griesmann G, Reid J, Federspiel M, Ames MM, Dingli D, Lacy MQ, Gertz MA, Schweikwart K, Welch A, Peng KW, Russell SJ. Pre-clinical data and preliminary patient results of intravenous MV-NIS to treat relapsed, refractory multiple myeloma. Blood 110(11):358A, 2007.
194. Aksoy P, Kocabas NA, Pelleymounter LL, Gilbert JA, Salavaggione OE, Eckloff BW, Wieben ED, Yee VC, Weinshilboum RM, Ames MM. Gemcitabine pharmacogenomics: deoxycytidine kinase (DCK) and cytidine monophosphate kinase (CMPK0 gene sequence variation and functional genomics. Clin Pharmcol Ther 83(Suppl 1):S18, 2008.
195. Li L, Fridley B, Kalari K, Jenkins GD, Batzler A, Hildebrandt MA, Safgren SL, Ames MM, Schaid DJ, Wang L. Pharmacogenomics of cytidine analogues: application of a cell-based model system. Clin Pharmacol Ther 83(Suppl 1):S17, 2008.